CAMBRIDGE, Mass. and BEIJING, China, March 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at two upcoming investor conferences:
- The Cowen and Company 38th Annual Health Care Conference in Boston on Monday, March 12, at 2:10 p.m. (ET); and
- The Barclays Global Healthcare Conference 2018 in Miami on Wednesday, March 14, at 4:20 p.m. (ET).
Live webcasts can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/ and archived replays will be available for 90 days following each event.
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 900 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i
Lucy Li, Ph.D.
+ 1 857-302-5663
i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.